Janus Henderson Investors logo

Janus Henderson Investors

Europe, England, United Kingdom, London

Description

Janus Henderson Investors is an asset manager that helps their clients achieve their financial goals.

Investor Profile

Janus Henderson Investors has backed more than 168 startups, with 19 new investments in the last 12 months alone. The firm has led 16 rounds, about 10% of its total and boasts 97 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Post Ipo Equity, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Canada, United Kingdom.
  • Strong thematic focus on Biotechnology, Health Care, Medical.
  • Led 2 rounds in the past year.

Stage Focus

  • Series B (30%)
  • Post Ipo Equity (29%)
  • Series C (17%)
  • Series A (12%)
  • Series D (6%)
  • Series Unknown (2%)
  • Private Equity (1%)
  • Series E (1%)
  • Series F (1%)
  • Series G (1%)

Country Focus

  • United States (88%)
  • Canada (3%)
  • United Kingdom (2%)
  • China (2%)
  • Singapore (1%)
  • Denmark (1%)
  • The Netherlands (1%)
  • Spain (1%)
  • India (1%)
  • Germany (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Life Science
  • Biopharma
  • Oncology
  • Health Diagnostics
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Janus Henderson Investors frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 29
Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 28
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 38
CA
North America, Massachusetts, United States, Boston
Co-Investments: 44
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 24
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 25
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 61
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 25
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 55
Boxer Capital
North America, Florida, United States, Windermere
Co-Investments: 28

Which angels does Janus Henderson Investors often collaborate with?

PT
North America, California, United States, San Francisco
Shared Deals: 1
SK
North America, California, United States, Los Angeles
Shared Deals: 1
JR
North America, California, United States, San Francisco
Shared Deals: 1
RK
North America, California, United States, Los Angeles
Shared Deals: 1

What are some of recent deals done by Janus Henderson Investors?

Pasithea Therapeutics

Miami Beach, Florida, United States

Pasithea Therapeutics is a biotechnology company that seeks to solve clinical problems such as mental health.

BiotechnologyHealth CareMental HealthTherapeutics
Post Ipo EquityNov 28, 2025
Amount Raised: $60,000,000
Starlab Space

Webster, Texas, United States

Developing the next-generation, AI-enabled commercial space station

Aerospace
Corporate RoundNov 20, 2025
Bambusa Therapeutics

Boston, Massachusetts, United States

Bambusa Therapeutics operates as biotechnology company.

BiotechnologyHealth CareLife ScienceMedical
Series ANov 17, 2025
Artios Pharma

Cambridge, Cambridgeshire, United Kingdom

Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.

BiopharmaBiotechnologyMedical Device
Series DNov 17, 2025
Amount Raised: $115,000,000
Galecto

Copenhagen, Hovedstaden, Denmark

Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.

BiotechnologyHealth CareHealth Diagnostics
Post Ipo EquityNov 10, 2025
Amount Raised: $284,900,000
Relmada Therapeutics

New York, New York, United States

Relmada Therapeutics is a biotech company addressing diseases of the central nervous system, with a focus on major depressive disorder.

BiotechnologyClinical TrialsPharmaceutical
Post Ipo EquityNov 4, 2025
Amount Raised: $100,000,000
Minerva Neuroscience

Cambridge, Massachusetts, United States

Minerva Neurosciences focuses on the development and commercialization of a portfolio of product candidates to treat CNS diseases.

BiopharmaBiotechnologyHealth CareNeuroscience
Post Ipo EquityOct 21, 2025
Amount Raised: $80,000,000
atai Life Sciences

Munich, Bayern, Germany

Atai Life Sciences develops innovative mental health treatments that address significant unmet medical needs.

BiotechnologyLife ScienceMental HealthNeuroscienceTherapeutics
Post Ipo EquityOct 16, 2025
Amount Raised: $149,500,000
Kailera Therapeutics

Waltham, Massachusetts, United States

Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.

BiotechnologyPharmaceuticalTherapeutics
Series BOct 14, 2025
Amount Raised: $600,000,000
Jade Biosciences

Waltham, Massachusetts, United States

Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.

Health CareTherapeutics
Post Ipo EquityOct 7, 2025
Amount Raised: $135,000,000